SRR1382532
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.603
- TNFA_SIGNALING_VIA_NFKB+0.578
- INTERFERON_ALPHA_RESPONSE+0.550
- INTERFERON_GAMMA_RESPONSE+0.549
- INFLAMMATORY_RESPONSE+0.543
- COMPLEMENT+0.425
- ALLOGRAFT_REJECTION+0.415
- COAGULATION+0.409
- PANCREAS_BETA_CELLS+0.399
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.398
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.547
- MYC_TARGETS_V1-0.497
- DNA_REPAIR-0.482
- MITOTIC_SPINDLE-0.408
- E2F_TARGETS-0.396
- MYC_TARGETS_V2-0.391
- PROTEIN_SECRETION-0.379
- G2M_CHECKPOINT-0.283
- PEROXISOME-0.264
- FATTY_ACID_METABOLISM-0.262
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3H71BH6Q | Ganglioglioma | — | 0.953 |
| 2 | SRR1469495 | GTEX | — | 0.945 |
| 3 | SRR1329885 | GTEX | — | 0.938 |
| 4 | BS_699TN5RN | Ganglioglioma | — | 0.936 |
| 5 | SRR597977 | GTEX | — | 0.936 |
| 6 | sclc0617_S65.txt | — | cohortMD2 | 0.935 |
| 7 | MNG663 | — | — | 0.935 |
| 8 | SRR1470111 | GTEX | — | 0.929 |
| 9 | SRR821602 | GTEX | — | 0.927 |
| 10 | sclcWD22563_S71.txt | — | cohortMD2 | 0.927 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.603 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.578 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.549 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.543 | Idelalisib | — uncovered |
| COMPLEMENT | 0.425 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.415 | Idelalisib | — uncovered |
| COAGULATION | 0.409 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.399 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.398 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.351 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.322 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.288 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.253 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.247 | Idelalisib | — uncovered |
| HYPOXIA | 0.197 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.188 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.183 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.168 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.167 | Inavolisib | — uncovered |